Approximately 40% of GBM patients harbor methylated MGMT, silencing expression in tumor cells, enhancing chemosensitivity and survival (progression-free survival (PFS) = 10.3 months, overall survival (OS) = 21.7 months) [2]. Here, MGMT is linked to neoplasm.